Doctors' Understanding of Survival Statistics (MPIB)
This study has been completed.
Sponsor:
Max Planck Institute for Human Development
Collaborator:
Dartmouth-Hitchcock Medical Center
Information provided by:
Max Planck Institute for Human Development
ClinicalTrials.gov Identifier:
NCT00981019
First received: September 18, 2009
Last updated: July 20, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The probably most commonly used measure for expressing the pay-offs of early detection and treatment are survival rates. Yet, over time and groups this metric comes with several biases and thus, is not reliable for judging such benefits. Epidemiologists recommend using reduction of disease-specific mortality rates instead, which is unbiased. The purpose of the study is to investigate how primary care physicians understand and use different survival measures for determining the benefit of cancer screening tests.
| Condition |
|---|
|
Screening |
| Study Type: | Observational |
| Study Design: | Observational Model: Ecologic or Community Time Perspective: Prospective |
| Official Title: | Study of Primary Care Physicians' Understanding and Use of Different Survival Measures |
Further study details as provided by Max Planck Institute for Human Development:
Primary Outcome Measures:
- Number of Physicians (=Participants) Recommending the Screening [ Time Frame: 25 minutes (mean duration of the survey) ] [ Designated as safety issue: No ]The aim of the study was to learn how different medical cancer screening statistics would influence doctors' recommendation behavior and their effectiveness judgments of screening tests. For that reason the online survey study presented physicians with four different medical statistics (e.g., 5-year survival) within four successive scenarios and asked after each scenario whether they would recommend the screening to a (hypothetical) patient given the data. Options to answer are: Definitely yes, Probably yes, Probably no, Definitely no, Can't decide.
Secondary Outcome Measures:
- Number of Physicians (= Participants) Assuming a Benefit of Screening [ Time Frame: 25 minutes (mean duration of the survey) ] [ Designated as safety issue: No ]Physicians are faced with four different medical statistics about the effect of screening (e.g., 5-year survival) within four successive scenarios and after each scenario asked whether they assume the screening to be beneficial given the statistical information. Options to answer are: yes, no, can't decide. If yes, then participants are further asked to describe this benefit by the following categories: Very large, large, moderate, small, very small.
| Enrollment: | 778 |
| Study Start Date: | December 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
mortality*incidence*5-year survival*early stage
Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
|
Eligibility| Ages Eligible for Study: | 30 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
301 primary care physicians (internal, general, and family medicine physicians)
Criteria
Inclusion Criteria:
- primary care physicians (internal, general, and family medicine physicians)
Exclusion Criteria:
- all other types of physicians
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00981019
Locations
| Germany | |
| Max Planck Institute for Human Development | |
| Berlin, Germany, 14195 | |
Sponsors and Collaborators
Max Planck Institute for Human Development
Dartmouth-Hitchcock Medical Center
Investigators
| Principal Investigator: | Odette Wegwarth, Dr. | Max Planck Institute for Human Development |
More Information
Additional Information:
No publications provided by Max Planck Institute for Human Development
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr. Odette Wegwarth, Max Planck Institute for Human Development/ Harding Center for Risk Literacy |
| ClinicalTrials.gov Identifier: | NCT00981019 History of Changes |
| Other Study ID Numbers: | MPIB-01-SM |
| Study First Received: | September 18, 2009 |
| Results First Received: | May 20, 2011 |
| Last Updated: | July 20, 2011 |
| Health Authority: | Germany: Ethics Commission |
Keywords provided by Max Planck Institute for Human Development:
|
survival rates risk communication screening counselling screening recommendation understanding of medical risk |
ClinicalTrials.gov processed this record on May 16, 2013